|
|
|
|
|||||
|
|
|
Novo Nordisk A/S (NYSE:NVO) is one of the Best Extremely Profitable Stocks to Buy Right Now. On July 18, Novo Nordisk A/S (NYSE:NVO) announced signing a Memorandum of Understanding with Fangzhou Inc., which is a leading internet healthcare solution provider.
The collaboration focuses on managing serious chronic diseases like diabetes and obesity through AI and innovative healthcare technologies. Fangzhou will use its AI applications and smart healthcare ecosystem alongside Novo Nordisk A/S (NYSE:NVO)’s expertise in diabetes and obesity treatment. Both companies aim to develop health management services that include guidance, reminders, treatment monitoring, and health education.
Novo Nordisk A/S (NYSE:NVO) is an international pharmaceutical company specializing primarily in diabetes care and obesity disorders.
While we acknowledge the potential of NVO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
| Jul-25 | |
| Jul-25 | |
| Jul-25 | |
| Jul-24 | |
| Jul-23 | |
| Jul-23 | |
| Jul-23 | |
| Jul-23 | |
| Jul-22 | |
| Jul-22 | |
| Jul-22 | |
| Jul-21 | |
| Jul-20 | |
| Jul-18 | |
| Jul-18 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite